Outcomes With Local Therapy and Tyrosine Kinase Inhibition in Patients With ALK/ROS1/RET-Rearranged Lung Cancers.
Hubbeling H, Choudhury N, Flynn J, Zhang Z, Falcon C, Rusch VW, Park BJ, Ziv E, Shaverdian N, Gelblum DY, Shepherd AF, Simone CB 2nd, Wu AJ, Gomez DR, Drilon A, Rimner A.
Hubbeling H, et al. Among authors: shaverdian n.
JCO Precis Oncol. 2022 Oct;6:e2200024. doi: 10.1200/PO.22.00024.
JCO Precis Oncol. 2022.
PMID: 36201714
Free PMC article.